Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease
Source: Expert Opinion on Drug Delivery, Volume 8, Number 4, April 2011 , pp. 451-466(16)
Publisher: Informa Healthcare
Abstract:Introduction: Cystic fibrosis (CF) is a multisystem genetic disorder, which usually results in significant respiratory dysfunction. At present there is no cure for CF, but advances in pharmacotherapy have gradually increased the life expectancy of CF patients. As many drugs used in the therapy of CF are delivered by inhalation, the demand for effective and convenient inhalational CF drug formulations will grow as CF patients live longer. Knowledge of the current limitations in inhalational CF drug delivery is critical in identifying new opportunities and designing rational delivery strategies.
Areas covered: This review discusses current and emerging therapeutic agents for CF therapy, selected physiological challenges to effective inhalational medication delivery, and various approaches to overcoming these challenges. The reader will find an integrated view of the known inhalational drug delivery challenges and the rationales for recent investigational inhalational drug formulations.
Expert opinion: An ideal drug/gene delivery system to CF airways should overcome the tenacious sputum, which presents physical, chemical and biological barriers to effective transport of therapeutic agents to the targets and various cellular challenges.
Document Type: Research Article
Affiliations: 1: 1Purdue University, College of Pharmacy, Department of Industrial and Physical Pharmacy, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA ++1 765 496 9608; ++1 765 494 6545;, Email: firstname.lastname@example.org 2: 2Advocate Lutheran General Children's Hospital, Divisions of Pediatric Critical Care Medicine and Pediatric Pulmonology, Department of Pediatrics, 1775 Dempster St, Park Ridge, IL 60068, USA 3: 3Jilin University, College of Life Science, Research Center for Drug Metabolism, Changchun 130021, PR China
Publication date: April 2011